Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.40
BRLI's Cash to Debt is ranked higher than
55% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BRLI: 0.40 )
BRLI' s 10-Year Cash to Debt Range
Min: 0.02   Max: 1.39
Current: 0.4

0.02
1.39
Equity to Asset 0.67
BRLI's Equity to Asset is ranked higher than
76% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. BRLI: 0.67 )
BRLI' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.73
Current: 0.67

0.33
0.73
Interest Coverage 34.11
BRLI's Interest Coverage is ranked higher than
61% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. BRLI: 34.11 )
BRLI' s 10-Year Interest Coverage Range
Min: 0.85   Max: 52.32
Current: 34.11

0.85
52.32
F-Score: 5
Z-Score: 7.29
M-Score: -2.14
WACC vs ROIC
4.92%
15.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.41
BRLI's Operating margin (%) is ranked higher than
85% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. BRLI: 10.41 )
BRLI' s 10-Year Operating margin (%) Range
Min: -6.49   Max: 12.39
Current: 10.41

-6.49
12.39
Net-margin (%) 5.87
BRLI's Net-margin (%) is ranked higher than
82% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. BRLI: 5.87 )
BRLI' s 10-Year Net-margin (%) Range
Min: -9.28   Max: 8.27
Current: 5.87

-9.28
8.27
ROE (%) 16.75
BRLI's ROE (%) is ranked higher than
92% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. BRLI: 16.75 )
BRLI' s 10-Year ROE (%) Range
Min: -35.97   Max: 24.15
Current: 16.75

-35.97
24.15
ROA (%) 10.91
BRLI's ROA (%) is ranked higher than
93% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. BRLI: 10.91 )
BRLI' s 10-Year ROA (%) Range
Min: -13.68   Max: 14.14
Current: 10.91

-13.68
14.14
ROC (Joel Greenblatt) (%) 32.17
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. BRLI: 32.17 )
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.55   Max: 43.5
Current: 32.17

-19.55
43.5
Revenue Growth (3Y)(%) 14.70
BRLI's Revenue Growth (3Y)(%) is ranked higher than
89% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. BRLI: 14.70 )
BRLI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.3   Max: 22.4
Current: 14.7

1.3
22.4
EBITDA Growth (3Y)(%) 10.50
BRLI's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. BRLI: 10.50 )
BRLI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.1   Max: 37.3
Current: 10.5

-18.1
37.3
EPS Growth (3Y)(%) 9.20
BRLI's EPS Growth (3Y)(%) is ranked higher than
82% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. BRLI: 9.20 )
BRLI' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.8   Max: 196.2
Current: 9.2

-61.8
196.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BRLI Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 447,026 sh (New)
Steven Cohen 21,122 sh (New)
Chuck Royce 258,934 sh (+123.99%)
Mario Gabelli 58,700 sh (+4.08%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 15,400 sh (-50.64%)
» More
Q2 2014

BRLI Guru Trades in Q2 2014

John Hussman 50,000 sh (New)
Paul Tudor Jones 19,717 sh (+28.03%)
Chuck Royce 304,334 sh (+17.53%)
Chase Coleman 720,000 sh (unchged)
Steven Cohen 8,000 sh (unchged)
Jean-Marie Eveillard Sold Out
Manning & Napier Advisors, Inc Sold Out
Mario Gabelli 58,500 sh (-0.34%)
» More
Q3 2014

BRLI Guru Trades in Q3 2014

John Hussman 59,000 sh (+18.00%)
Paul Tudor Jones 21,700 sh (+10.06%)
Chase Coleman 720,000 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 58,000 sh (-0.85%)
Chuck Royce 280,900 sh (-7.70%)
» More
Q4 2014

BRLI Guru Trades in Q4 2014

Joel Greenblatt 11,951 sh (New)
Steven Cohen 46,800 sh (New)
Paul Tudor Jones 28,610 sh (+31.84%)
Mario Gabelli 59,000 sh (+1.72%)
John Hussman 59,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Chuck Royce 206,300 sh (-26.56%)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.20
BRLI's P/E(ttm) is ranked higher than
97% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 19.20 )
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34   Max: 35.69
Current: 19.2

9.34
35.69
Forward P/E 14.66
BRLI's Forward P/E is ranked higher than
95% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 14.66 )
N/A
PE(NRI) 19.20
BRLI's PE(NRI) is ranked higher than
97% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 19.20 )
BRLI' s 10-Year PE(NRI) Range
Min: 9.33   Max: 35.91
Current: 19.2

9.33
35.91
P/B 2.97
BRLI's P/B is ranked higher than
74% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. BRLI: 2.97 )
BRLI' s 10-Year P/B Range
Min: 1.77   Max: 5.8
Current: 2.97

1.77
5.8
P/S 1.13
BRLI's P/S is ranked higher than
92% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. BRLI: 1.13 )
BRLI' s 10-Year P/S Range
Min: 0.61   Max: 1.98
Current: 1.13

0.61
1.98
PFCF 77.47
BRLI's PFCF is ranked higher than
71% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 77.47 )
BRLI' s 10-Year PFCF Range
Min: 16.27   Max: 958
Current: 77.47

16.27
958
POCF 32.89
BRLI's POCF is ranked higher than
79% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 32.89 )
BRLI' s 10-Year POCF Range
Min: 11.04   Max: 197.75
Current: 32.89

11.04
197.75
EV-to-EBIT 11.12
BRLI's EV-to-EBIT is ranked higher than
96% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 11.12 )
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 22.1
Current: 11.12

5.9
22.1
PEG 1.10
BRLI's PEG is ranked higher than
98% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 1.10 )
BRLI' s 10-Year PEG Range
Min: 0.36   Max: 1.33
Current: 1.1

0.36
1.33
Shiller P/E 25.33
BRLI's Shiller P/E is ranked higher than
93% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 25.33 )
BRLI' s 10-Year Shiller P/E Range
Min: 15.42   Max: 128.17
Current: 25.33

15.42
128.17
Current Ratio 2.45
BRLI's Current Ratio is ranked higher than
70% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. BRLI: 2.45 )
BRLI' s 10-Year Current Ratio Range
Min: 1.11   Max: 3.11
Current: 2.45

1.11
3.11
Quick Ratio 2.30
BRLI's Quick Ratio is ranked higher than
73% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BRLI: 2.30 )
BRLI' s 10-Year Quick Ratio Range
Min: 1.08   Max: 2.9
Current: 2.3

1.08
2.9
Days Inventory 16.16
BRLI's Days Inventory is ranked higher than
92% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. BRLI: 16.16 )
BRLI' s 10-Year Days Inventory Range
Min: 5.94   Max: 15.79
Current: 16.16

5.94
15.79
Days Sales Outstanding 114.07
BRLI's Days Sales Outstanding is ranked higher than
62% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. BRLI: 114.07 )
BRLI' s 10-Year Days Sales Outstanding Range
Min: 91.06   Max: 162.14
Current: 114.07

91.06
162.14

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.87
BRLI's Price/Net Current Asset Value is ranked higher than
77% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 4.87 )
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 1.1   Max: 50
Current: 4.87

1.1
50
Price/Tangible Book 3.50
BRLI's Price/Tangible Book is ranked higher than
82% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. BRLI: 3.50 )
BRLI' s 10-Year Price/Tangible Book Range
Min: 0.92   Max: 8.73
Current: 3.5

0.92
8.73
Price/DCF (Projected) 2.21
BRLI's Price/DCF (Projected) is ranked higher than
86% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 2.21 )
BRLI' s 10-Year Price/DCF (Projected) Range
Min: 1.86   Max: 36.33
Current: 2.21

1.86
36.33
Price/Median PS Value 0.89
BRLI's Price/Median PS Value is ranked higher than
88% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BRLI: 0.89 )
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 1.81
Current: 0.89

0.11
1.81
Price/Peter Lynch Fair Value 1.29
BRLI's Price/Peter Lynch Fair Value is ranked higher than
98% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 1.29 )
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61   Max: 1.4
Current: 1.29

0.61
1.4
Price/Graham Number 1.73
BRLI's Price/Graham Number is ranked higher than
95% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRLI: 1.73 )
BRLI' s 10-Year Price/Graham Number Range
Min: 0.3   Max: 5.26
Current: 1.73

0.3
5.26
Earnings Yield (Greenblatt) 9.00
BRLI's Earnings Yield (Greenblatt) is ranked higher than
95% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BRLI: 9.00 )
BRLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 17
Current: 9

4.5
17
Forward Rate of Return (Yacktman) 16.08
BRLI's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. BRLI: 16.08 )
BRLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.9   Max: 34.9
Current: 16.08

0.9
34.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:BFR.Germany,
Bio-Reference Laboratories Inc is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It also offers laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The Company is engaged in esoteric testing, molecular diagnostics, anatomical pathology, genetics, womens health and correctional health care. The Company has a network of approximately 116 patient service centers located in the Northeast (in New York metropolitan super-regional area) for collection of patient specimens. It conducts business in New York State counties, as well as in New Jersey, Maryland, Pennsylvania, Delaware and Connecticut. It offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, phlebotomy services and phlebotomy draw stations. The Company operates a clinical knowledge management service through its PSIMedica business unit. The system uses customer data from laboratory results, pharmaceutical data, claims data and other data sources provide administrative and clinical decision support systems that enable customers to provide quality and efficient healthcare to their populations. It also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its competitors in the New York metropolitan area are Quest Diagnostics (DGX) and Laboratory Corporation of America (LH). The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.
» More Articles for BRLI

Headlines

Articles On GuruFocus.com
Small cap high short interest (Predictability = 5), Part 1 Oct 16 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
DaVita Seems to be a High-Growth Company Aug 20 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
4 Attractive Small-Cap Growth + Value Stocks You Have Never Heard Of Apr 16 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 
Historical Short Interest Of Stocks – New Feature Announcement Jan 17 2014 
New Feature Announcement: Stocks With The Highest Short Interest Dec 12 2013 
comment on BRLI May 11 2013 

More From Other Websites
BioReference Laboratories Partners With Organizations Accelerating Medical Innovation Apr 13 2015
BioReference Laboratories Partners With Organizations Accelerating Medical Innovation Apr 13 2015
BIO REFERENCE LABORATORIES INC Financials Mar 17 2015
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Other Events Mar 13 2015
BIO REFERENCE LABORATORIES INC Files SEC form 10-Q, Quarterly Report Mar 09 2015
Bio-Reference (BRLI) in Focus: Stock Tumbles 7.7% - Tale of the Tape Mar 06 2015
Bio-Reference Laboratories Inc Earnings Call scheduled for 10:30 am ET today Mar 05 2015
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 05 2015
Bio-Reference Laboratories, Inc. Reports Over 15% Increase in Revenue; Net Income Up Over 100%, Year... Mar 05 2015
Bio-Reference Laboratories posts 1Q profit Mar 05 2015
Bio-Reference Laboratories posts 1Q profit Mar 05 2015
Bio-Reference Laboratories, Inc. Reports Over 15% Increase in Revenue; Net Income Up Over 100%, Year... Mar 05 2015
Q1 2015 Bio-Reference Laboratories Inc Earnings Release - Before Market Open Mar 05 2015
Four Hot Stocks You'll Want To Keep On Your Radar Feb 27 2015
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2015 Feb 26 2015
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2015 Feb 26 2015
BioReference Laboratories, Inc. Launches OnkoSight(TM), an Advanced Tumor Sequencing Program Feb 25 2015
BioReference Laboratories, Inc. Launches OnkoSight(TM), an Advanced Tumor Sequencing Program Feb 25 2015
GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing... Feb 17 2015
Henry Schein (HSIC) Beats Q4 Earnings, Revenues in Line - Analyst Blog Feb 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK